Vetmedin- CA1 Chewable Tablets 1.25mg, 50 Count

Vetmedin-CA1 Chewable Tablets 1.25mg, 50 Count

Sold ONLY to licensed veterinarians and pharmacies. Submit license if not already on file. Fax :: 800-640-3274
Licensed Professional Price: $38.08
Copy of License Required [No Prescriptions Please]
NDC: 0010-4610-01

Stock Status:In Stock

Product Code: 20230


VETMEDIN-CA1 Chewable Tablets


Cardiac drug for oral use in dogs only

VETMEDIN-CA1 (pimobendan) is indicated for the delay of onset of congestive heart failure in dogs with Stage B2 preclinical myxomatous mitral valve disease. Stage B2 preclinical myxomatous mitral valve disease (MMVD) refers to dogs with asymptomatic MMVD that have a moderate or loud mitral murmur due to mitral regurgitation and cardiomegaly.

VETMEDIN-CA1 supplied as oblong half-scored chewable tablets containing 1.25 or 5 mg pimobendan per tablet. Pimobendan is a non-sympathomimetic, non-glycoside inotropic drug with vasodilatative properties. Pimobendan exerts a stimulatory myocardial effect by a dual mechanism of action consisting of an increase in calcium sensitivity of cardiac myofilaments and inhibition of phosphodiesterase (Type III). Pimobendan exhibits vasodilating activity by inhibiting phosphodiesterase III activity.

Dosage and Administration:
VETMEDIN-CA1 should be administered orally at a total daily dose of 0.23 mg/lb (0.5 mg/kg) body weight, using a suitable combination of whole or half tablets. The total daily dose should be divided into 2 portions that are not necessarily equal, and the portions should be administered approximately 12 hours apart (i.e., morning and evening). The tablets are scored, and the calculated dosage should be provided to the nearest half tablet increment.

Contraindications: Do not administer VETMEDIN-CA1 in cases of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons.
Do not administer VETMEDIN-CA1 to dogs with Stage A or B1 preclinical MMVD due to the risk of cardiac pathology associated with exaggerated hemodynamic responses to VETMEDIN-CA1.

Precautions: For use only in dogs with preclinical MMVD that have a moderate or loud mitral murmur due to mitral regurgitation and cardiomegaly. A diagnosis of MMVD should be made by means of a comprehensive physical and cardiac examination which should include radiography and echocardiography.
Stage B2 cardiomegaly is diagnosed based on meeting all three of the following criteria:
  • Radiographic vertebral heart score (VHS) >10.5
  • Echocardiographic left atrium/aorta ratio (LA/Ao ratio) ≥1.6
  • Echocardiographic left ventricular internal diastolic diameter normalized to body weight (LVIDDN) ≥1.7
Echocardiographic examination is recommended in all cases to diagnose MMVD and confirm cardiomegaly. If therapy is initiated prior to the development of cardiomegaly, treated dogs are at risk for cardiac pathology associated with exaggerated hemodynamic responses to VETMEDIN-CA1.
If only radiographic examination is possible, cardiomegaly may be diagnosed in cases where the VHS ≥11.5 and the vertebral left atrial size (VLAS) ≥3.0. If radiographic cardiomegaly does not meet both of these criteria, an echocardiogram should be performed prior to the initiation of therapy with VETMEDIN-CA1. VETMEDIN-CA1 has not been evaluated in dogs receiving concomitant heart medications. The safety of VETMEDIN-CA1 has not been established in dogs with asymptomatic heart disease caused by etiologies other than MMVD. The safe use of VETMEDIN-CA1 has not been evaluated in dogs younger than 6 months of age, dogs with congenital heart defects, dogs with diabetes mellitus or other serious metabolic diseases, dogs used for breeding, or pregnant or lactating bitches.
Not for use in humans. Keep this and all medications out of reach of children.

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed.

Storage: Store at 20° to 25°C (68° to 77°F), excursions permitted between 15° and 30°C (between 59° and 86°F).

How Supplied:

VETMEDIN®-CA1 (pimobendan) Chewable Tablets: Available as 1.25 and 5 mg oblong half-scored chewable tablets - 50 tablets per bottle.
NDC 0010-4610-01 - 1.25 mg - 50 tablets
NDC 0010-4612-01 - 5 mg - 50 tablets

Boehringer Ingelheim Vetmedical

Rx Medication Sold Only To Licensed Veterinarians & Pharmacies. Current License Must Be On File Prior To Shipping.

Share your knowledge of this product. Be the first to write a review »